These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 22949894)

  • 1. Dipeptidyl Peptidase IV Inhibitor Improves Insulin Resistance and Steatosis in a Refractory Nonalcoholic Fatty Liver Disease Patient: A Case Report.
    Itou M; Kawaguchi T; Taniguchi E; Oriishi T; Sata M
    Case Rep Gastroenterol; 2012 May; 6(2):538-44. PubMed ID: 22949894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dipeptidyl peptidase IV inhibitors: therapeutic potential in nonalcoholic fatty liver disease.
    Yilmaz Y; Atug O; Yonal O; Duman D; Ozdogan O; Imeryuz N; Kalayci C
    Med Sci Monit; 2009 Apr; 15(4):HY1-5. PubMed ID: 19333209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of sitagliptin on nonalcoholic fatty liver disease in diet-induced obese rats.
    Akaslan SB; Degertekin CK; Yilmaz G; Cakir N; Arslan M; Toruner FB
    Metab Syndr Relat Disord; 2013 Aug; 11(4):243-50. PubMed ID: 23544853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intestinal TGR5 agonism improves hepatic steatosis and insulin sensitivity in Western diet-fed mice.
    Finn PD; Rodriguez D; Kohler J; Jiang Z; Wan S; Blanco E; King AJ; Chen T; Bell N; Dragoli D; Jacobs JW; Jain R; Leadbetter M; Siegel M; Carreras CW; Koo-McCoy S; Shaw K; Le C; Vanegas S; Hsu IH; Kozuka K; Okamoto K; Caldwell JS; Lewis JG
    Am J Physiol Gastrointest Liver Physiol; 2019 Mar; 316(3):G412-G424. PubMed ID: 30605011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of insulin-sensitizing agents in the treatment of nonalcoholic steatohepatitis.
    Van Wagner LB; Rinella ME
    Therap Adv Gastroenterol; 2011 Jul; 4(4):249-63. PubMed ID: 21765869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE.
    Bian H; Zhu X; Xia M; Yan H; Chang X; Hu X; Pan B; Guo W; Li X; Gao X
    Endocr Pract; 2020 Apr; 26(4):444-453. PubMed ID: 31968197
    [No Abstract]   [Full Text] [Related]  

  • 7. Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!
    Ranjbar G; Mikhailidis DP; Sahebkar A
    Metabolism; 2019 Dec; 101():154001. PubMed ID: 31672448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A dipeptidyl peptidase-IV inhibitor improves hepatic steatosis and insulin resistance by AMPK-dependent and JNK-dependent inhibition of LECT2 expression.
    Hwang HJ; Jung TW; Kim BH; Hong HC; Seo JA; Kim SG; Kim NH; Choi KM; Choi DS; Baik SH; Yoo HJ
    Biochem Pharmacol; 2015 Nov; 98(1):157-66. PubMed ID: 26297911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sitagliptin reduces insulin resistance and improves rat liver steatosis via the SIRT1/AMPKα pathway.
    Shen T; Xu B; Lei T; Chen L; Zhang C; Ni Z
    Exp Ther Med; 2018 Oct; 16(4):3121-3128. PubMed ID: 30214535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease.
    Budd J; Cusi K
    Curr Diab Rep; 2020 Oct; 20(11):59. PubMed ID: 33015726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic effects of the dipeptidyl peptidase-IV inhibitor, sitagliptin, on non-alcoholic steatohepatitis in FLS-ob/ob male mice.
    Onoyama T; Koda M; Okamoto T; Kishina M; Matono T; Sugihara T; Murawaki Y
    Mol Med Rep; 2015 Nov; 12(5):6895-902. PubMed ID: 26397061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beneficial effect of omarigliptin on diabetic patients with non-alcoholic fatty liver disease/non-alcoholic steatohepatitis.
    Hattori S; Nomoto K; Suzuki T; Hayashi S
    Diabetol Metab Syndr; 2021 Mar; 13(1):28. PubMed ID: 33691757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatic steatosis in obese Chinese children.
    Chan DF; Li AM; Chu WC; Chan MH; Wong EM; Liu EK; Chan IH; Yin J; Lam CW; Fok TF; Nelson EA
    Int J Obes Relat Metab Disord; 2004 Oct; 28(10):1257-63. PubMed ID: 15278103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
    Belfort R; Harrison SA; Brown K; Darland C; Finch J; Hardies J; Balas B; Gastaldelli A; Tio F; Pulcini J; Berria R; Ma JZ; Dwivedi S; Havranek R; Fincke C; DeFronzo R; Bannayan GA; Schenker S; Cusi K
    N Engl J Med; 2006 Nov; 355(22):2297-307. PubMed ID: 17135584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metformin Alleviates Hepatic Steatosis and Insulin Resistance in a Mouse Model of High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease by Promoting Transcription Factor EB-Dependent Autophagy.
    Zhang D; Ma Y; Liu J; Deng Y; Zhou B; Wen Y; Li M; Wen D; Ying Y; Luo S; Shi C; Pu G; Miao Y; Zou C; Chen Y; Ma L
    Front Pharmacol; 2021; 12():689111. PubMed ID: 34366846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effects of telmisartan, sitagliptin and metformin alone or in combination on obesity, insulin resistance, and liver and pancreas remodelling in C57BL/6 mice fed on a very high-fat diet.
    Souza-Mello V; Gregório BM; Cardoso-de-Lemos FS; de Carvalho L; Aguila MB; Mandarim-de-Lacerda CA
    Clin Sci (Lond); 2010 Jun; 119(6):239-50. PubMed ID: 20415664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A cross-sectional study assessing dietary intake and physical activity in Canadian patients with nonalcoholic fatty liver disease vs healthy controls.
    Da Silva HE; Arendt BM; Noureldin SA; Therapondos G; Guindi M; Allard JP
    J Acad Nutr Diet; 2014 Aug; 114(8):1181-94. PubMed ID: 24631112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pathogenetic substantiation of complex treatment of nonalcoholic steatohepatitis and steatosis in patients with pre-diabetes and type 2 diabetes].
    Чопей ІВ; Івачевська ВВ; Чубірко КІ; Гряділь ТІ; Гечко ММ
    Wiad Lek; 2017; 70(2):169-173. PubMed ID: 28511152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Relationship between the severity of liver damage and the serum leptin level for nonalcoholic fatty liver disease].
    Kim KO; Park SH; Park CH; Han TH; Yoo KS; Kim JH; Lee MS; Kim DJ; Park CK; Cho HD
    Korean J Hepatol; 2005 Mar; 11(1):51-8. PubMed ID: 15788885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review.
    Shyangdan D; Clar C; Ghouri N; Henderson R; Gurung T; Preiss D; Sattar N; Fraser A; Waugh N
    Health Technol Assess; 2011 Nov; 15(38):1-110. PubMed ID: 22059955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.